The companies’ outlook upgrades were rare enough to allow BioMérieux to stand out from the crowd. The in vitro testing ace thus provided an excellent reagent for its stock (+4.2%), an excellent antidote to the stock market sourings of September. Not only did organic sales growth in the second quarter exceed forecasts (+10.1% versus +6.5%) but it also marked an acceleration compared to the previous quarter.
